Recombinant Human SMAD1 Protein, His-tagged

• Cat.No.: SMAD1-161H
• Product Overview: Recombinant Human SMAD1, transcript variant 1, fused with His tag at N-terminal was expressed in E. coli.

Specification

• Description: The protein encoded by this gene belongs to the SMAD, a family of proteins similar to the gene products of the Drosophila gene 'mothers against decapentaplegic' (Mad) and the C. elegans gene Sma. SMAD proteins are signal transducers and transcriptional modulators that mediate multiple signaling pathways. This protein mediates the signals of the bone morphogenetic proteins (BMPs), which are involved in a range of biological activities including cell growth, apoptosis, morphogenesis, development and immune responses. In response to BMP ligands, this protein can be phosphorylated and activated by the BMP receptor kinase. The phosphorylated form of this protein forms a complex with SMAD4, which is important for its function in the transcription regulation. This protein is a target for SMAD-specific E3 ubiquitin ligases, such as SMURF1 and SMURF2, and undergoes ubiquitination and proteasome-mediated degradation. Alternatively spliced transcript variants encoding the same protein have been observed.
• Source: E. coli
• Species: Human
• Tag: His
• Form: 25mM Tris, pH8.0, 150 mM NaCl, 10% glycerol, 1 % Sarkosyl.
• Molecular Mass: 52.1 kDa
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Concentration: >50 ug/mL as determined by microplate BCA method

Gene Information

• Gene Name: SMAD1 SMAD family member 1 [ Homo sapiens ]
• Official Symbol: SMAD1
• Synonyms: SMAD1; SMAD family member 1; MAD, mothers against decapentaplegic homolog 1 (Drosophila) , MADH1, SMAD, mothers against DPP homolog 1 (Drosophila); mothers against decapentaplegic homolog 1; JV4 1; MADR1; MAD homolog 1; Mad-related protein 1; TGF-beta signaling protein 1; mothers against DPP homolog 1; SMAD, mothers against DPP homolog 1; MAD, mothers against decapentaplegic homolog 1; transforming growth factor-beta signaling protein 1; transforming growth factor-beta-signaling protein 1; BSP1; JV41; BSP-1; JV4-1; MADH1
• Gene ID: 4086
• mRNA Refseq: NM_005900
• Protein Refseq: NP_005891
• MIM: 601595
• UniProt ID: Q15797

Reviews

06/08/2022

Whether I am investigating enzymatic activity, studying protein-protein interactions, or testing its role in signaling pathways, the SMAD1 protein consistently performs exceptionally well.

08/08/2021

This versatility allows me to explore different aspects of my research with confidence and accuracy.

05/02/2018

The SMAD1 protein's excellent functionality makes it highly suitable for various trial applications.

Q&As

What technologies are commonly used to study the expression and activity of SMAD1 in clinical research?

Techniques like Western blotting, immunohistochemistry, and qRT-PCR are commonly employed to study SMAD1 expression and activity in clinical research.

How might targeting SMAD1 have implications for anti-cancer therapies?

Modulating SMAD1 activity could be explored as a potential strategy for developing anti-cancer therapies, particularly in cancers where the TGF-β pathway is dysregulated.

Are there any known genetic mutations in the SMAD1 gene associated with human diseases?

Yes, mutations in the SMAD1 gene have been identified in certain individuals with congenital disorders and developmental abnormalities.

How does SMAD1 interact with other proteins in the TGF-β pathway?

SMAD1 forms complexes with other SMAD proteins, transducing signals from TGF-β receptors to the nucleus, where they regulate gene expression.

How can SMAD1 be targeted for therapeutic interventions in bone-related disorders?

Targeting SMAD1 or its downstream effectors in the TGF-β pathway may offer potential therapeutic strategies for bone-related disorders, such as osteoporosis.